NTR-441 / Neutrolis - LARVOL DELTA

Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients (clinicaltrials.gov) - P1 | N=52 | Terminated | Sponsor: Neutrolis | N=92 ➔ 52 | Trial completion date: Nov 2022 ➔ Jun 2023 | Recruiting ➔ Terminated; the emergence of the omicron variant of COVID-19 lead to insufficient enrollment

Enrollment change • Trial completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients (clinicaltrials.gov) - P1 | N=92 | Recruiting | Sponsor: Neutrolis | Trial completion date: Jun 2022 ➔ Nov 2022 | Trial primary completion date: Jun 2022 ➔ Nov 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients (clinicaltrials.gov) - P1; N=92; Recruiting; Sponsor: Neutrolis; Trial completion date: Nov 2021 ➔ Jun 2022; Trial primary completion date: Nov 2021 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients (clinicaltrials.gov) - P1; N=92; Recruiting; Sponsor: Neutrolis

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease

Neutrolis Announces Development Of First-In-Class Treatment Targeting Neutrophil Extracellular Traps (NETs) For Patients With Severe COVID-19 (PRNewswire) - "Neutrolis...today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19....Several independent investigators have observed NETs in the lungs of autopsied COVID-19 patients, and observed that NETs biomarkers in patient blood correlate with the clinical severity of COVID-19....'We found NETs congesting blood vessels in the lungs of all patients. Clearing these NETs with NTR-441 to restore blood flow may help patients survive COVID-19...'"

Biomarker • Infectious Disease • Novel Coronavirus Disease